
Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxQR1BEM2xmSjdndk1TT0VpX1hWNHJ1M0pFZW9VQVBBTmJndlJ1b25mTWl6dEQyeW1XUktHUU1EZHdiZFlWdmRvd1lsSWtYdUhVMTFvam1CZjJkU1JtNkV4UFNuSGtMaDJFdUJGUGZ4aFBtR0p0akRXOXduaTVrTndSV0pRQzJZM1pPTlJtbG50YW1DNnYza3NZT3pqeGZQRVFDTkFQTlA0YVlYajhHNFFKOEdLUVpmdmRJZjdGZENLakJKaDY4MF80OGRVT2dfY0FtdmwzZ3I0VjEyZHUtbnV6Y2VvSXZlRDNJR0pLRkRjSE9FUWNudTBtS2VFVlJ4UzVyXzZJbjhLbHMtLWNtWG5iNnE2LVRHZm0yaWc0?oc=5" target="_blank">Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials</a>&nbsp;&nbsp;<font color="#6f6f6f">Cureus</font>

